Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia

Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) which is shown superiority more than imatinib in first-line treatment for sufferers of CML. [2]. Nilotinib (AMN107) is normally a fresh BCR/ABL inhibitor and it is extremely selective for ABL kinase and 30-flip stronger than imatinib. Nilotinib provides created hematological and cytogenetic replies… Continue reading Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia